# Safety and Efficacy of Diacerein 1% Ointment for Subjects With Epidermolysis Bullosa Simplex (EBS)

> **NCT03154333** · PHASE2 · TERMINATED · sponsor: **Castle Creek Pharmaceuticals, LLC** · enrollment: 54 (actual)

## Conditions studied

- Epidermolysis Bullosa Simplex

## Interventions

- **DRUG:** diacerein 1% ointment
- **DRUG:** A placebo ointment

## Key facts

- **NCT ID:** NCT03154333
- **Lead sponsor:** Castle Creek Pharmaceuticals, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-06-01
- **Primary completion:** 2018-10-15
- **Final completion:** 2018-10-31
- **Target enrollment:** 54 (ACTUAL)
- **Why stopped:** Futility
- **Last updated:** 2019-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03154333

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03154333, "Safety and Efficacy of Diacerein 1% Ointment for Subjects With Epidermolysis Bullosa Simplex (EBS)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03154333. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*